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Hematopoietic cell transplantation outcomes are strongly influenced by the extent of genetic 
matching between donors and recipients; a closer match enhances the chances of engraftment, and 
decreases the risk of graft-versus-host disease (GVHD). Histocompatibility is determined by human 
leucocyte antigen (HLA) genes, which define tissue type and are known for their extensive DNA 
sequence diversity. Each alternative arrangement encodes different forms, or allelic variants, of the 
HLA genes, which can affect the production of antibodies. The resulting genetically determined 
differences in antibodies are called allotypes, which enable "high resolution" donor matching for HLA 
alleles. The risks of adverse effects after transplantation can thus be reduced using DNA-based 
laboratory testing of blood serum from patients and donors. HLA-C allotype mismatching is a 
particularly important risk factor for the development of GVHD, but there are indications that some 
HLA-C mismatches are better tolerated than others. 
In 2013, a large collaborative HIV study demonstrated that the surface expression of HLA-C can be 
quantified through measurement of mean fluorescence intensity (MFI), and that the intensity level 
was specific for each allotype (Apps et al., 2013). The technique enabled another unique 
international collaborative study, in which samples from 1,975 patients were retrospectively analyzed 
and correlated with treatment outcome. All patients had received a hematopoietic cell transplant 
from unrelated donors with whom they had one single HLA-C mismatch. The results of the extensive 
study were recently published in Blood, with Fred Hutch's Dr. Effie Petersdorf as first author. In 
addition to Dr. Petersdorf, Drs. Ted Gooley and Mari Malkki from the Clinical Research Division also 
contributed. 
"In the current study, we hypothesized that some HLA mismatches are better tolerated than others, 
and that the level of cell surface expression of the patient's mismatched HLA allotype contributes to 
its immunogenicity," Dr. Petersdorf said. 
Indeed, their findings indicated that the risks of post-transplant complications were influenced by the 
expression level of the non-shared HLA-C. Lower risk of GVHD was demonstrated for mismatches 
with lower expression levels, whereas highly expressed mismatches were significantly associated 
with adverse effects such as acute GVHD, non-relapse mortality and mortality. "We demonstrate that 
when the patient's mismatched HLA-C allotype is expressed at higher levels, risks of GVHD and  
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transplant-related mortality are higher than when the allotype is expressed at lower levels. These 
data indicate a role for HLA expression levels in the immunogenicity of HLA mismatching in 
transplantation," Dr. Petersdorf said. 
A possible explanation for the observed correlation is that less expressed allotypes are more likely to 
escape detection by the recipient, thereby avoiding an adverse immune reaction. For patients who 
lack an HLA-matched donor these results could provide a crucial approach for increasing the use of 
selected non-matched donors, instead of flat-out disqualifying all mismatches. "The HLA-C allotypes 
encoded by patients may be assessed prior to transplantation as to whether there are 0, 1 or 2 high-
expression alleles. When HLA-C matched donors are not available, avoidance of mismatching for 
the high-expression HLA-C allotype in the patient may help to lower risks of GVHD after 
transplantation," Dr. Petersdorf explained. 
Up next for the team of researchers is further exploration of the mechanisms involved in regulating 
HLA-C expression, as they are not yet entirely known. The more information they can gather, the 
better our understanding of transplant-related immune responses in humans will be. 
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